Robeco Institutional Asset Management B.V. Has $22.36 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Robeco Institutional Asset Management B.V. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 19.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 605,529 shares of the biotechnology company's stock after buying an additional 100,240 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.22% of Exelixis worth $22,356,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Coppell Advisory Solutions LLC bought a new position in Exelixis in the fourth quarter valued at approximately $25,000. Colonial Trust Co SC lifted its position in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 765 shares in the last quarter. Principal Securities Inc. lifted its position in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Exelixis in the 4th quarter worth $50,000. Finally, Hurley Capital LLC bought a new position in Exelixis during the 4th quarter worth about $68,000. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

Exelixis stock traded up $0.58 during midday trading on Friday, reaching $43.67. 3,523,886 shares of the company's stock were exchanged, compared to its average volume of 2,447,120. The stock's 50-day simple moving average is $41.07 and its 200 day simple moving average is $37.34. The firm has a market cap of $11.91 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 0.88 and a beta of 0.28. Exelixis, Inc. has a 52 week low of $21.82 and a 52 week high of $49.62.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Morgan Stanley restated an "overweight" rating and issued a $47.00 price target (up from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Wall Street Zen lowered Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Finally, JMP Securities lifted their price objective on shares of Exelixis from $47.00 to $50.00 and gave the company a "market outperform" rating in a report on Monday, June 23rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.22.

Insider Activity

In related news, Director Tomas J. Heyman sold 4,544 shares of Exelixis stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total transaction of $201,253.76. Following the completion of the sale, the director now owns 32,470 shares of the company's stock, valued at approximately $1,438,096.30. The trade was a 12.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 126,383 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the completion of the transaction, the executive vice president now owns 446,459 shares in the company, valued at approximately $21,412,173.64. This trade represents a 22.06% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock valued at $21,024,817 over the last three months. Insiders own 2.82% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.